A Phase 1, Open-Label, Parallel-Group, Adaptive Study Evaluating the Pharmacokinetics of a Single Oral Dose of Momelotinib in Subjects with Hepatic Impairment (HI) and Healthy Matched Control Subjects with Normal Hepatic Function
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Momelotinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Pharmacokinetics
- 28 Dec 2017 Results of this and other study (renal impairment, profile:270241), published in the Journal of Clinical Pharmacology.
- 20 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics